9 recruiting, 2 withdrawn, 1 active not recruiting, 1 enrolling by invitation. 14 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Recruiting 9, Withdrawn 2, Active not recruiting 1, Enrolling by invitation 1, Not yet recruiting 1 |
| Phase 2 | 3 | Recruiting 2, Withdrawn 1 |
Follow Antiphospholipid Syndrome: new trials by email Literature Review of Antiphospholipid Syndrome trials Research Report on Antiphospholipid Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I, Dose Escalation, Open-label, Multicenter Study of EA5 Injection in Adults With APS and Recurrent Thrombosis EA5 - Antiphospholipid Syndrome (APS), Thrombosis | Phase 1 | Active not recruiting | Shanghai Lanyi Therapeutics Co., Ltd. | 12 | 2026-05-25 | 2026-06-08 |
| YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Diffuse Systemic Sclerosis | Phase 1 | Not yet recruiting | Children's Hospital of Fudan University | 12 | 2026-03-01 | 2026-02-27 |
| An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus, Lupus Nephritis (LN) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-11-24 | 2026-03-04 |
| Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Systemic Sclerosis | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-11-13 | 2026-03-02 |
| A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-08-13 | 2026-10-21 |
| A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-08-04 | 2026-10-21 |
| Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases anti-CD19 CAR T cell therapy - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Recruiting | Peking University Third Hospital | 9 | 2025-07-01 | 2026-09-22 |
| A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 12 | 2025-05-19 | 2026-10-21 |
| Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) RAY121 - Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP) | Phase 1 | Enrolling by invitation | Chugai Pharmaceutical | 144 | 2024-12-09 | 2026-07-17 |
| Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases HBI0101 CART - Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM) | Phase 1 | Recruiting | Polina Stepensky | 120 | 2024-09-01 | 2026-05-06 |
| Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) RAY121 - Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP) | Phase 1 | Recruiting | Chugai Pharmaceutical | 144 | 2024-08-19 | 2026-07-22 |
| Daratumumab in Primary Antiphospholipid Syndrome Daratumumab - Autoimmune Disorders | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 22 | 2023-05-26 | 2026-10-21 |
| Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss Low dose steroids - Antiphospholipid Syndrome | Phase 1 / Phase 2 | Withdrawn | Imperial College London | 2005-10-01 | 2024-02-26 | |
| Hematopoietic Stem Cell Transplantation in Patients With Antiphospholipid Syndrome Stem Cell Transplantation - ANTIPHOSPHOLIPID SYNDROME | Phase 1 | Withdrawn | Richard Burt, MD | 2005-08-01 | 2012-04-11 |
Myositis (8) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (7) · Lupus Erythematosus, Systemic (7) · Scleroderma, Systemic (5) · Sjogren's Syndrome (4) · Autoimmune Diseases (3) · Lupus Nephritis (3) · Arthritis, Rheumatoid (2) · Behcet Syndrome (2) · Dermatomyositis (2) · Pemphigoid, Bullous (2) · Purpura, Thrombocytopenic, Idiopathic (2) · Recurrence (2) · Immunoglobulin G4-Related Disease (1)
Immune System Diseases (14) · Autoimmune Diseases (11) · Cardiovascular Diseases (10) · Connective Tissue Diseases (10) · Muscular Diseases (10) · Musculoskeletal Diseases (10) · Nervous System Diseases (10) · Neuromuscular Diseases (10) · Skin Diseases (10) · Skin and Connective Tissue Diseases (10) · Vascular Diseases (10) · Skin Diseases, Vascular (9) · Vasculitis (9) · Eye Diseases (7) · Systemic Vasculitis (7)
Stem Cell Transplantation (1) · Steroids (1) · daratumumab (1)
China Immunotech (Beijing) Biotechnology Co., Ltd. (5) · Chugai Pharmaceutical (2) · Children's Hospital of Fudan University (1) · Imperial College London (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Peking University Third Hospital (1) · Polina Stepensky (1) · Richard Burt, MD (1) · Shanghai Lanyi Therapeutics Co., Ltd. (1)
China (8) · United States (3) · Australia (2) · Austria (2) · Bulgaria (2) · Canada (2) · Croatia (2) · Czechia (2) · France (2) · Germany (2) · Hungary (2) · Italy (2) · Japan (2) · Netherlands (2) · Norway (2)
Doruk Erkan, M.D., M.P.H. (1) · Jason Knight, M.D., Ph.D. (1) · Raj Rai, MRCOG (1) · Richard Burt, MD (1)
2005 (1)